Abstract:Abstract Background Anti-T2 biological therapies have proven to effectively reduce acute exacerbations and daily doses of oral steroids in severe eosinophilic asthma. Despite the remarkable clinical efficacy, there are usually only moderate improvements in airflow limitation, suggesting that other measures of lung function like small airway dysfunction (SAD) might better reflect the clinical response. We aimed to investigate if measures of small airway function would predict and correlate with the clinical response to anti-T2 therapy. Methods We studied data of patients who were previously included in the German prospective longitudinal All Age Asthma Cohort (ALLIANCE) that recruits asthma patients of all severity grades and inflammatory phenotypes. The selection criteria for this analysis were adult patients with severe eosinophilic asthma under treatment with anti-T2 biological agents. Asthma control was assessed by asthma control test (ACT) and number of severe exacerbations. Small airway function was assessed by the frequency dependence of resistance (FDR, R5-20)) derived from impulse oscillometry (IOS) and the mean forced expiratory flow between 25 and 75% of the forced vital capacity (FEF 25-75 ). We also studied air trapping (RV and RV/TLC), blood eosinophils and FeNO. Patients were classified into responders and partial or non-responders. Clinical response was defined as at least 50% reduction in annualized severe exacerbations and daily oral steroid doses accompanied with a minimum increase of 3 points in the ACT score. We used a Receiver Operator Characteristic (ROC) to study the capacity of FDR in predicting clinical response compared to other clinical variable like blood eosinophils. We studied the correlation between FDR measures and clinical response, represented by the ACT score and number of exacerbations, using linear regressions. Results 20 patients were included (mean age, 59 ± 9 years; 60% female; mean body mass index (BMI), 27.6 ± 5.4 kg/m 2 ; mean absolute blood eosinophils, 570 ± 389/μl; mean number of severe exacerbations 12 months prior to initiating the biological therapy, 5.0 ± 3; mean predicted FEV1, 76 ± 21%; mean predicted FDR, 224 ± 140%; mean daily prednisolone dose, 6.4 ± 4.9 mg; mean ACT score, 15 ± 5). Responders had significantly higher baseline FDR compared to partial or non-responders but similar FEV1, FEF 25–75, RV and RV/TLC. ROC analysis showed that the combination of FDR and blood eosinophils had the best predictive capacity of the clinical response among all tested clinical markers (FeNO, FEV1, FDR, blood eosinophils) with an AUC of 85% [67–100%], (CI = 0.95, p = 0.01). Linear regressions indicated better associations between improvements in FDR and ACT score (R 2 = 0.42, p = 0.001) than with FEV1 and ACT score (R 2 = 0.25, p = 0.013). Likewise, we observed better associations between improvements in FDR and reduction of exacerbations (R 2 = 0.41, p = 0.001) than with FEV1 (R 2 = 0.20, p = 0.025). Conclusion Our data suggest that severe SAD may represent a distinct phenotype of eosinophilic asthma that substantially improves under anti-T2 biological therapy. Measures of small airway function might be useful in selecting appropriate patients qualifying for anti-T2 biological therapy in addition to blood eosinophil count.

Small Airway Dysfunction in Asthma is Associated with Perceived Respiratory Symptoms, Non-Type 2 Airway Inflammation, and Poor Responses to Therapy

Does Small-Airways Dysfunction Predispose to Greater Perceived Respiratory Symptoms During Bronchoconstriction in Asthma?

Small airway dysfunction links asthma exacerbations with asthma control and health-related quality of life

Small Airway Dysfunction Links Asthma Severity with Physical Activity and Symptom Control

Small-Airway Function Variables in Spirometry, Fractional Exhaled Nitric Oxide, and Circulating Eosinophils Predicted Airway Hyperresponsiveness in Patients with Mild Asthma.

Small airway inflammation in atypical asthma

Changes of Inflammatory Factors in Patients with Small Airway Dysfunction

Characteristics of Airway Inflammatory Cells and Cytokines in Patients with Gastroesophageal Refluxinduced "Asthma"

Small-Airway Dysfunction is Involved in the Pathogenesis of Asthma: Evidence from Two Mouse Models.

Analysis of influencing factors of small airway dysfunction in adults

Small-airway Dysfunction among Non-Cystic Bronchiectasis Patients with Different Bronchiectasis Severity Index

Sex Differences of Small Airway Function and Fractional Exhaled Nitric Oxide in Patients with Mild Asthma

Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study

Increases in peripheral SIRT1: A new biological characteristic of asthma.

Airway Inflammation, Bronchial Hyperresponsiveness, and Anti-Asthma Therapy Responses in Cough Variant Asthma and Classic Asthma with FEV1%≥80% Predicted

Monitoring Small Airway Dysfunction in Connective Tissue Disease-Related Interstitial Lung Disease: a Retrospective and Prospective Study.

Small Airways Disease Affects Aerosol Deposition in Children with Severe Asthma: A Functional Respiratory Imaging Study

New insights in small airway dysfunction of childhood asthma

If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease

When patient-reported respiratory symptoms shed light on pathophysiology in adult asthma: a cross-sectional study

[A Study of Airway Reactivity and Nature of Chronic Asthmatic Bronchitis].